Investigating how TREM2 interacts with molecules in Alzheimer's disease
TREM2-endogenous ligand interactions in Alzheimer disease
['FUNDING_R01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-11113821
This study is looking at a protein called TREM2 and how changes in our genes might affect its role in Alzheimer's disease, with the goal of finding new ways to improve treatments for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-11113821 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the TREM2 protein in Alzheimer's disease, particularly how genetic variations affect its ability to interact with specific molecules in the brain. The study aims to identify these molecules and explore how they influence TREM2's function, which is crucial for immune responses in the brain. By examining these interactions, researchers hope to uncover new insights into the mechanisms of Alzheimer's disease and potential therapeutic targets. Patients may benefit from advancements in treatment strategies based on these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with late-onset Alzheimer's disease, particularly those with known genetic risk factors related to TREM2.
Not a fit: Patients with early-onset Alzheimer's disease or those without genetic variations in TREM2 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for Alzheimer's disease by enhancing TREM2's immune activity.
How similar studies have performed: Previous research has shown promising results in understanding TREM2's role in Alzheimer's disease, indicating that this approach has potential for significant findings.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SONG, YUHUA — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: SONG, YUHUA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Alzheimer's disease pathology